GNMK - Will GenMark Diagnostics' Stock Keep Rising?
In what can only be described as a rough year for public markets, a select group of stocks has managed to buck the trend. Investors seek to uncover these hidden gems to help their portfolios thrive through turbulent times. Healthcare, and biotechnology in particular, has been a bright spot, outperforming the broader markets.
GenMark Diagnostics (NASDAQ: GNMK) ranks among this year's top performers. Investors in the San Diego-based developer of diagnostic tests and equipment have seen their shares soar 149% since the start of 2020. While many companies have reduced or withdrawn 2020 financial guidance, GenMark increased its projected revenue twice, spurred by demand for its rapid test for COVID-19.
Image Source: Getty Images.